Stock listing

LSE:SCLP Scancell Holdings PLC Share Price

Home listing (LSE) of Scancell Holdings PLC

Follow Scancell Holdings PLC into a list and get an email when it puts out news.

Share price · LSE:SCLP

87.40p GBX (pence) -1.60 (-1.8%)

Close on Oct 30, 2026

Past year -9.4% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
86.50p – 90.00p GBX (pence)Oct 30, 2026
Volume
77,114 sharesOct 30, 2026
Market cap
£118.6M GBPAt the close on Oct 30, 2026 · price × 135.7M shares outstanding
52-week range
86.50p – 295.00p GBX (pence)Lowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
£241,801 GBPMedian day 134,833 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Scancell Holdings PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:SCLP · Home87.40p GBX (pence)-1.60 (-1.8%)77,11489.00p90.00p86.50p89.00pClose on Oct 30, 2026

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · LSE:SCLP · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
87.40p-1.60-1.8%89.00p90.00p86.50p77,114
89.00p0.000.0%89.00p90.00p88.00p106,170
89.00p0.000.0%89.00p90.00p88.31p98,494
89.00p-1.00-1.1%90.00p92.00p88.00p659,867
90.00p-1.00-1.1%91.00p92.00p88.00p134,631
91.00p0.000.0%91.00p92.00p90.00p86,331
91.00p+0.80+0.9%92.50p95.00p90.00p66,057
90.20p-2.80-3.0%89.50p95.00p89.50p87,877
93.00p0.000.0%93.50p94.00p92.40p15,087
93.00p0.000.0%93.50p94.00p93.00p8,254
93.00p-0.50-0.5%93.50p94.00p93.00p27,871
93.50p0.000.0%93.50p94.00p93.00p61,640
93.50p0.000.0%93.50p94.00p93.35p144,853
93.50p0.000.0%93.50p94.20p93.00p106,583
93.50p+0.50+0.5%93.50p94.00p93.00p89,627
93.00p-1.00-1.1%94.00p95.00p93.00p164,806
94.00p0.000.0%94.00p95.00p93.00p25,049
94.00p-0.50-0.5%94.50p95.00p93.00p130,603
94.50p+0.50+0.5%94.00p96.00p93.60p431,941
94.00p-1.00-1.1%94.00p95.00p93.00p82,443
95.00p+1.50+1.6%93.50p95.00p93.00p188,195
93.50p-0.50-0.5%94.00p94.00p93.00p135,035
94.00p-1.00-1.1%94.50p95.00p93.26p54,318
95.00p-0.50-0.5%95.50p96.00p94.00p111,623
95.50p0.000.0%95.50p96.00p95.00p84,920
95.50p-0.50-0.5%96.00p97.00p95.01p59,085
96.00p-1.00-1.0%98.00p99.00p95.25p199,138
97.00p0.000.0%98.00p99.00p97.00p115,318
97.00p-1.00-1.0%98.00p99.00p96.00p110,968
98.00p+0.50+0.5%97.50p99.00p96.80p129,088
97.50p-1.00-1.0%98.50p99.00p97.00p140,299
98.50p-0.50-0.5%98.50p99.20p98.00p88,829
99.00p+0.50+0.5%98.50p99.00p98.00p92,005
98.50p-1.00-1.0%99.50p102.00p98.00p103,500
99.50p-2.00-2.0%101.50p101.65p98.00p165,795
101.50p+0.50+0.5%100.50p102.00p100.00p1,029,377
101.00p+0.50+0.5%101.00p105.50p100.00p1,134,292
100.50p+1.50+1.5%99.00p105.00p98.00p724,681
99.00p+1.00+1.0%98.00p100.00p98.00p296,682
98.00p+2.40+2.5%96.00p99.00p95.90p256,517
95.60p+0.10+0.1%95.50p97.00p95.00p79,104
95.50p-0.50-0.5%96.00p97.00p95.35p236,125
96.00p0.000.0%96.00p97.00p95.00p163,009
96.00p-1.50-1.5%97.50p99.00p95.00p116,642
97.50p+1.30+1.4%96.00p99.00p95.65p118,201
96.20p-0.80-0.8%97.00p98.00p95.00p211,026
97.00p0.000.0%97.00p98.00p96.00p93,174
97.00p-1.00-1.0%98.00p98.20p96.30p212,988
98.00p+1.00+1.0%97.00p100.00p97.00p365,063
97.00p+2.00+2.1%95.50p98.00p95.00p938,933
95.00p-1.00-1.0%96.00p97.00p95.00p799,523
96.00p+1.00+1.1%97.00p98.00p95.00p801,231
95.00p-0.40-0.4%96.00p97.00p95.00p133,443
95.40p-0.60-0.6%96.00p97.00p95.00p176,909
96.00p+0.40+0.4%96.00p97.00p95.00p88,671
95.60p-0.40-0.4%96.00p97.00p95.00p138,168
96.00p0.000.0%96.00p97.00p95.00p99,248
96.00p+1.00+1.1%95.00p97.00p94.50p396,959
95.00p+0.50+0.5%94.50p95.00p94.00p451,897
94.50p-0.50-0.5%96.00p97.00p94.00p451,826
95.00p-2.40-2.5%98.00p98.20p95.00p819,291
97.40p-1.60-1.6%98.50p99.00p97.00p176,425
99.00p0.000.0%99.00p100.00p96.00p482,646
99.00p+1.50+1.5%97.50p100.00p97.00p550,075
97.50p-0.50-0.5%98.00p99.00p97.00p209,940
98.00p-1.00-1.0%99.00p99.00p97.00p393,675
Ticker
LSE:SCLP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Calls

Replays

  • Scancell Holdings (LSE:SCLP) — Clinical and Corporate Update

    Wed, Jun 25, 2025 · 6:00 AM ET

    Watch Transcript

Latest news

Notice of AGM

Oct 23, 2026

Closed 91.00p (0.0%) on Oct 23, 2026

Result of General Meeting

Oct 20, 2026

Closed 93.00p (0.0%) on Oct 20, 2026

Issue of Equity, Director Dealing & Voting Rights

Oct 15, 2026

Closed 93.50p (0.0%) on Oct 15, 2026

Preliminary Results

Oct 9, 2026

Closed 93.00p (-1.1%) on Oct 9, 2026

Notice of GM

Oct 2, 2026

Closed 95.00p (+1.6%) on Oct 2, 2026

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

Sep 24, 2026

Closed 96.00p (-1.0%) on Sep 24, 2026

Scancell to Present at the H.C. Wainwright Sept 26

Sep 3, 2026

Closed 95.50p (-0.5%) on Sep 3, 2026

iSCIB1+ MHRA CTA Approval for Ph3 trial

Aug 19, 2026

Closed 96.00p (+1.1%) on Aug 19, 2026

Extension of Option Exercise Period

Jul 31, 2026

Closed 97.50p (-0.5%) on Jul 31, 2026

Correction: Merger and Financing

Jul 24, 2026

Closed 94.00p (-10.5%) on Jul 24, 2026

All Scancell Holdings PLC news

Financings

  • Private placement of private placement (PIPE Financing)

    Oct 9, 2026

    Update: US$39.1M · US$0.1205 a share · Leerink Partners +2

    Dealers: Leerink Partners, TD Cowen, H.C. Wainwright & Co.

    Buyers: Redmile Funds (44,813,278 Non-Voting Ordinary Shares); Vulpes (9,128,630 ADSs (representing 91,286,307 Ordinary Shares)); Dr Phil L'Huillier (24,896 ADSs)

    Insiders: CEO Dr Phil L'Huillier to subscribe for 24,896 ADSs; related parties Redmile Funds and Vulpes also participating

    Use of proceeds: Fund the registrational Phase 3 study of iSCIB1+ in advanced melanoma through key clinical milestones

    Announced Jul 23, 2026 · Update Jul 24, 2026 · Update Oct 9, 2026

  • Loan facility, partly convertible into Ordinary Shares, with warrants

    Oct 9, 2026

    Update: up to US$25M · warrants to subscribe for Ordinary Shares pro-rata to drawdowns, equal to 4.5% of each…

    Buyers: BlackRock (lender under a loan facility of up to $25.0 million); funds and accounts managed by BlackRock (Lender under loan facility of up to US$25,000,000); Kreos Capital VIII Aggregator SCSp (Warrants pro rata to drawdowns under the Loan Facility)

    Use of proceeds: To initiate and execute the global registrational Phase 3 trial of lead programme iSCIB1+

    Announced Jul 23, 2026 · Update Jul 24, 2026 · Update Sep 24, 2026 · Update Oct 9, 2026

  • Private placement of new Ordinary Shares

    Jul 24, 2026

    Update: about US$12M · GBX 9 a share · Panmure Liberum Limited

    Dealers: Panmure Liberum Limited (lead)

    Announced Jul 23, 2026 · Update Jul 24, 2026

  • Ordinary Shares

    Jul 24, 2026

    Update: up to US$3M · GBX 9 a share

    Announced Jul 23, 2026 · Update Jul 24, 2026

Read by 6ix AI from the company's releases

Decks

Scancell Holdings PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 332 in all · newest Oct 23, 2026 · oldest 2008
Calls
1 call with a replay · 1 with a transcript · latest Jun 25, 2025
Decks
20 decks · latest August 2026

Where Scancell Holdings PLC is listed

ListingExchangeCountryCurrency
LSE:SCLP · Home listing · This pageLSEUnited KingdomGBX
OTC:SCNLFOTCUnited StatesUSD
AQUIS:SCLP.GBAQUISUnited KingdomGBX
Frankfurt:SCPFrankfurtGermanyEUR

Log in to ask 6ix AI your own questions about Scancell Holdings PLC.